Market Access and Patients Support Programs

• Patient support programmes (PSPs) are increasingly important for Pharmaceutical Companies. The ability to wrap services around their leading-edge therapies, in order to deliver superior patient outcomes, drive differentiation and strengthen patient and healthcare professional (HCP) relationships, and will increasingly determine success in the future.
• PSPs help delivers a better overall patient outcome and, as the industry increasingly pivots to more outcomes-based reimbursement models, improving the actual patient outcome will be a critical success factor. A good patient support programme will be a factor in treatment approvals and market authorisations and will increase patient enrolment.
• Patient Support Programmes are a top priority for Integral Health Limited. We know that even single-digit increases in market share will drive significant improvements in top and bottom-line performance for the pharma company while, at the same time, reducing the overall cost of care to the ecosystem. Thus, PSPs are a clear win-win for everyone.